Navigation Links
Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
Date:11/11/2008

CRANBURY, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced President and CEO, John F. Crowley, will make a presentation at the 5th Annual Lazard Capital Markets Healthcare Conference in New York on Tuesday, November 18, 2008, at 5:10 p.m. EST.

A webcast and audio archive of the presentation will be available at the Company's Web site at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days until December 18, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Amicus' press releases are available at http://www.amicustherapeutics.com

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... 2015 R-Japan Co.,Ltd. obtained the license of cell ... Medicine from the Ministry of Health, Labour and Welfare Kinki ... The fact that R- Japan ... from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, ... provide stem cell manufacturing service to medical institutions. As of ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... a webinar to provide advanced scientific research into new classes of Nanoscale Graphene-based ... energy. Touted as 'the wonder material of the 21st Century' by the ...
(Date:6/30/2015)... Americord Registry, one of the fastest growing cord blood banks ... at Kirkland & Ellis LLP, as the newest member of ...   "We are thrilled about Andrew Horne,s ... , CEO of Americord. "He brings a wealth of knowledge ... growth and vision." Andrew Horne is ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... to be Indicated ... for Use in First-Line Therapy, SEATTLE, ... announced today that it has submitted a supplemental,Biologics License Application ... of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation therapy after remission induction in ...
... Inc.,(NYSE: FRX ), an international manufacturer and ... Second Quarter financial results,before the U.S. stock market ... at 10:00 AM EDT, Forest will host a ... Operating Officer and Frank Perier, Senior,Vice President-Finance and ...
... 1 SpectraScience, Inc. (OTC,Bulletin Board: SCIE), a ... has shipped its non-invasive WavSTAT(R) Optical Biopsy,System to ... clinical,value of the Optical Biopsy System as an ... or cancer in the esophagus.,This marks the final ...
Cached Biology Technology:Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings 2University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 2University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 3University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 4
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
(Date:6/18/2015)... 2015 This report analyzes the worldwide markets ... Product Segments, which includes Immunoassay Analyzers and Reagents: Enzyme ... Immunoassay Systems, and Nephelometric Immunoassay Systems. The report provides ... , Japan , ... Latin America , and Rest of World. ...
(Date:6/17/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that Xiaomi, one of the world,s largest mobile ... ® family of capacitive touchscreen solutions and ... for its latest smartphones, the Xiaomi Mi Note ... in-cell display solutions and DDICs in discrete display ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... the McKnight Brain Institute of the University of Florida ... other diseases by plundering the secrets of regeneration from ... newts, starfish and flatworms. , Fueled by about $6 ... funds, "The Regeneration Project" will connect scientists who work ...
... how different species use common genes to control their ... to accommodate their own features. The findings, which were ... Small’s laboratories in NYU’s Center for Developmental Genetics, offer ... species. The study is published in the latest issue ...
... medical practice that an antiretroviral drug widely used to treat ... own in patients co-infected with HIV. Their findings demonstrate ... drugs used to treat the AIDS virus. , "Our results ... has been shown to be active against HIV - it ...
Cached Biology News:Research project tackles 'regeneration' gap 2Research project tackles 'regeneration' gap 3NYU scientists identify how development of different species uses same genes with distinct features 2Widely used hepatitis B drug spurs HIV drug resistance 2Widely used hepatitis B drug spurs HIV drug resistance 3
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: